{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:16:45Z","timestamp":1789064205435,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021356","name":"Fondation du Grand d\u00e9fi Pierre Lavoie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021356","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association de la Neurofibromatose du Qu\u00e9bec"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s11060-024-04624-3","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T20:01:41Z","timestamp":1709668901000},"page":"447-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of trametinib on the neuropsychological profile of NF1 patients"],"prefix":"10.1007","volume":"167","author":[{"given":"Eve","family":"Lalancette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9dith","family":"Cantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-\u00c8ve","family":"Routhier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Mailloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorsa Sadat","family":"Kiaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Larouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Tabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ellezam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"D\u00e9carie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Th\u00e9oret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-\u00c9laine","family":"M\u00e9tras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"McKeown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis H.","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Vairy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallie","family":"Coltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Legault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Bouffet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Lafay-Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Hukin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Erker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Caru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Dehaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Jabado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Perreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lipp\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"issue":"1","key":"4624_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archderm.141.1.71","volume":"141","author":"M Lammert","year":"2005","unstructured":"Lammert M et al (2005) Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 141(1):71\u201374","journal-title":"Arch Dermatol"},{"issue":"4","key":"4624_CR2","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.cell.2012.06.034","volume":"150","author":"Y Wang","year":"2012","unstructured":"Wang Y et al (2012) ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell 150(4):816\u2013830","journal-title":"Cell"},{"issue":"7","key":"4624_CR3","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1212\/01.wnl.0000179303.72345.ce","volume":"65","author":"SL Hyman","year":"2005","unstructured":"Hyman SL, Shores A, North KN (2005) The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65(7):1037\u20131044","journal-title":"Neurology"},{"issue":"1","key":"4624_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00415-012-6620-5","volume":"260","author":"JM Payne","year":"2013","unstructured":"Payne JM et al (2013) Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials. J Neurol 260(1):214\u2013220","journal-title":"J Neurol"},{"issue":"3","key":"4624_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.conb.2004.04.001","volume":"14","author":"JD Sweatt","year":"2004","unstructured":"Sweatt JD (2004) Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 14(3):311\u2013317","journal-title":"Curr Opin Neurobiol"},{"issue":"3","key":"4624_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrn1346","volume":"5","author":"GM Thomas","year":"2004","unstructured":"Thomas GM, Huganir RL (2004) MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5(3):173\u2013183","journal-title":"Nat Rev Neurosci"},{"key":"4624_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.cortex.2014.10.019","volume":"64","author":"MJ Ribeiro","year":"2015","unstructured":"Ribeiro MJ et al (2015) Abnormal relationship between GABA, neurophysiology and impulsive behavior in neurofibromatosis type 1. Cortex 64:194\u2013208","journal-title":"Cortex"},{"key":"4624_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105881","volume":"174","author":"A Lacroix","year":"2022","unstructured":"Lacroix A et al (2022) Multimodal assessment of the GABA system in patients with fragile-X syndrome and neurofibromatosis of type 1. Neurobiol Dis 174:105881","journal-title":"Neurobiol Dis"},{"issue":"9","key":"4624_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1212\/WNL.0000000000003044","volume":"87","author":"IR Violante","year":"2016","unstructured":"Violante IR et al (2016) GABA deficiency in NF1: a multimodal [11C]-flumazenil and spectroscopy study. Neurology 87(9):897\u2013904","journal-title":"Neurology"},{"issue":"4","key":"4624_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","volume":"31","author":"KB Kim","year":"2013","unstructured":"Kim KB et al (2013) Phase II study of the MEK1\/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31(4):482","journal-title":"J Clin Oncol"},{"issue":"5","key":"4624_CR11","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/annonc\/mdv072","volume":"26","author":"G Blumenschein Jr","year":"2015","unstructured":"Blumenschein G Jr et al (2015) A randomized phase II study of the MEK1\/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Ann Oncol 26(5):894\u2013901","journal-title":"Ann Oncol"},{"issue":"26","key":"4624_CR12","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E et al (2016) Activity of selumetinib in neurofibromatosis type 1\u2013related plexiform neurofibromas. N Engl J Med 375(26):2550\u20132560","journal-title":"N Engl J Med"},{"issue":"15","key":"4624_CR13","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM et al (2020) Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 382(15):1430\u20131442","journal-title":"N Engl J Med"},{"key":"4624_CR14","doi-asserted-by":"crossref","unstructured":"Mueller S et al (2020) NFB-17. Mek inhibitor binimetinib shows clinical activity in children with neurofibromatosis type 1- associated plexiform neurofibromas: a report from pnoc and the nf clinical trials consortium. Neuro Oncol 22(Suppl 3): p 420\u20131","DOI":"10.1093\/neuonc\/noaa222.619"},{"issue":"1","key":"4624_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-6442-2","volume":"19","author":"S Perreault","year":"2019","unstructured":"Perreault S et al (2019) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01. BMC Cancer 19(1):1\u20139","journal-title":"BMC Cancer"},{"key":"4624_CR16","doi-asserted-by":"crossref","unstructured":"Perreault S et al (2021) Syst-04. tram-01: a phase 2 study of trametinib for patients with pediatric glioma with activation of the mapk\/erk pathway. Neuro-Oncology Advances 3(Supplement_4):iv9\u2013iv9","DOI":"10.1093\/noajnl\/vdab112.032"},{"issue":"7","key":"4624_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss BD et al (2021) NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J Clin Oncol 39(7):797\u2013806","journal-title":"J Clin Oncol"},{"issue":"1","key":"4624_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13229-021-00458-2","volume":"12","author":"SC Borrie","year":"2021","unstructured":"Borrie SC et al (2021) MEK inhibition ameliorates social behavior phenotypes in a Spred1 knockout mouse model for RASopathy disorders. Mol Autism 12(1):53","journal-title":"Mol Autism"},{"key":"4624_CR19","doi-asserted-by":"crossref","unstructured":"Walsh KS et al (2021) Impact of MEK inhibitor therapy on neurocognitive functioning in NF1. Neurol Genet 7(5): p e616","DOI":"10.1212\/NXG.0000000000000616"},{"key":"4624_CR20","doi-asserted-by":"crossref","unstructured":"Legius E et al (2021) Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 23(8): p 1506\u20131513","DOI":"10.1038\/s41436-021-01170-5"},{"key":"4624_CR21","volume-title":"San Antonio, TX: San Antonio","author":"DC Delis","year":"2001","unstructured":"Delis DC, Kaplan E, Kramer JH, Delis-Kaplan executive function system (D-KEFS). (2001) San Antonio, TX: San Antonio. The Psychological Corporation, TX"},{"key":"4624_CR22","unstructured":"Field A (2013) Discovering statistics using IBM SPSS statistics (4th ed.). London, England : SAGE Publications."},{"key":"4624_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jecp.2022.105441","volume":"221","author":"JA Dugan","year":"2022","unstructured":"Dugan JA, Bauer PJ (2022) Putting the pieces together: Cognitive correlates of self-derivation of new knowledge in elementary school classrooms. J Exp Child Psychol 221:105441","journal-title":"J Exp Child Psychol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04624-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04624-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04624-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T13:06:27Z","timestamp":1715778387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04624-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["4624"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04624-3","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}